4//SEC Filing
Kirchgraber Paul R 4
Accession 0001127602-23-005103
CIK 0000920148other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 2:57 PM ET
Size
8.5 KB
Accession
0001127602-23-005103
Insider Transaction Report
Form 4
Kirchgraber Paul R
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2023-02-11+483→ 14,211 total - Tax Payment
Common Stock
2023-02-13$248.13/sh−142$35,234→ 14,069 total - Exercise/Conversion
Restricted Stock Unit
2023-02-11−483→ 3,001 total→ Common Stock (483 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023.
- [F4]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001791393
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 2:57 PM ET
- Size
- 8.5 KB